BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Not yet recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2026

Conditions
Prostate Cancer Metastatic
Interventions
DIAGNOSTIC_TEST

Testosterone levels

Blood sample to determine testosterone levels

Trial Locations (3)

Unknown

Hospital Universitario Reina Sofía, Córdoba

Hospital Universitario Virgen de las Nieves, Granada

Hospital Universitario Virgen del Rocio, Seville

All Listed Sponsors
collaborator

Hospital Universitario Reina Sofia de Cordoba

OTHER_GOV

collaborator

Hospitales Universitarios Virgen del Rocío

OTHER

collaborator

Hospital Universitario Torrecárdenas

OTHER

collaborator

Hospital Neurotraumatologico de Jaen

OTHER

collaborator

Hospital San Carlos, Madrid

OTHER

collaborator

Institut Mutualiste Montsouris

OTHER

collaborator

San Raffaele University Hospital, Italy

OTHER

collaborator

Azienda Ospedaliera San Giovanni Battista

OTHER

collaborator

Chinese University of Hong Kong

OTHER

collaborator

Medical University Innsbruck

OTHER

collaborator

University of Padova

OTHER

collaborator

UMC Utrecht

OTHER

lead

Ignacio Puche Sanz

OTHER

NCT05530395 - BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC | Biotech Hunter | Biotech Hunter